PEB
23/05/2013 10:26
GENERAL
REL: 1026 HRS Pacific Edge Limited
GENERAL: PEB: National Accounts Manager Appointed for USA
23 May 2013
National Accounts Manager Appointed for USA
Michael Maltby has joined Pacific Edge Diagnostics USA (PEDUSA) as the new
Director of National Accounts and Payer Relations.
Pacific Edge Diagnostics USA, Chief Executive Officer Jackie Walker says
Michael has over 15 years experience in diagnostics, pharmaceutical, and
medical device sales and national accounts management with a great track
record of success.
Michael was most recently with Sequenom Center for Molecular Medicine and
prior to that spent 12 years with Prometheus Laboratories until it was sold
to Nestle Health Science. Michael has been instrumental in launching an
array of molecular diagnostic and therapeutic products.
"We are delighted to have Michael join the PEDUSA team. He will play a key
role in the launch of Cxbladder and its billing and reimbursement strategy
execution."
PEDUSA, a wholly owned subsidiary of Pacific Edge, received regulatory
approval in March to begin processing Cxbladder tests at its purpose built
laboratory in Hershey, Pennsylvania.
Michael Maltby joins a team, led by PEDUSA Chief Executive Officer Jackie
Walker, who have a wealth of experience in launching and managing biomedical
products in the USA, the world's largest health market.
For further information please contact:
David Darling
Chief Executive Officer
Pacific Edge Limited
P: +64 (3) 4795800
ABOUT PACIFIC EDGE
Pacific Edge Limited (NZX: PEB) is a New Zealand based cancer diagnostic
company specialising in the discovery and commercialisation of diagnostic and
prognostic technology for the early detection and monitoring of cancer.
Products in development and in clinical trials are accurate and simple to use
genomic and proteomic tools for the earlier detection, improved
characterisation and better management of gastric, bladder, colorectal
cancers and melanoma. The Company has recently completed and released its
first product for the detection of bladder cancer, Cxbladder, and is actively
marketing the product to urologists in New Zealand, Australia and soon to be
Spain and the USA.
www.pacificedge.co.nz
ABOUT PACIFIC EDGE DIAGNOSTICS
Pacific Edge takes its exciting cancer detection tests to market through its
wholly owned subsidiaries, Pacific Edge Diagnostics NZ Limited and Pacific
Edge Diagnostics USA Limited, and selected commercial partners in Australia
and Spain, Healthscope Pathology and Oryzon respectively.
www.pacificedgedx.com
ABOUT Cxbladder
Cxbladder is a non-invasive, accurate test that enables the early detection
of bladder cancer from a small volume of urine. It provides general
practitioners and urologists with a quick, cost effective and accurate
measure of the presence of the cancer and provides urologists with the
opportunity to reduce their reliance on the need for invasive tests such as
cystoscopy. The recently published, Journal of Urology in September 2012,
multi-centre international clinical study recruited 485 patients from
Australia and New Zealand. Results show that Cxbladder out-performed all
other benchmark technologies in the clinical trial and detected nearly all of
the tumours of concern to a urologist; At 85% specificity the test sees 100%
of T1, T2, T3, Tis and greater than 95% of high grade tumours.
www.cxbladder.com
ABOUT BLADDER CANCER
Globally, bladder cancer has the 9th highest incidence and the 4th highest
incidence for men. One of the early symptoms of bladder cancer is the
presence of blood in the urine, haematuria. People with haematuria often
present to their general practitioner before being referred on to a
urologist.
There are a number of 'at risk' occupations that have shown a much higher
incidence of bladder cancer. Fire fighters and fire control officers have
shown in a US study to have a twice the incidence of bladder cancer over non
fire fighters. Smoking is a significant contributing factor (over 50% in
males and 33% in females, and approximately one of every two new incidences
of bladder cancer is linked to smoking). Exposure to certain industrial
chemicals or carcinogens increases risks for some occupations e.g.
hairdressers, painters, printers, fire fighters and metal workers and
chemical engineers. Incidence increases with age so the older you are, the
greater the potential for bladder cancer.
Bladder cancer has a very high recurrence rate of approximately 50%-70% with
up to 30% of these recurring as later stage tumours. This is a higher
recurrence than for skin cancer! However, bladder cancers are highly
treatable, especially if detected in the early stages. If diagnosed early
there is a much higher probability of survival for early stage tumours
relative to later stage tumours. This makes timely and regular surveillance
and monitoring of this cancer a key element of the clinical process and of
the individual's annual healthcare plan.
End CA:00236558 For:PEB Type:GENERAL Time:2013-05-23 10:26:41
